Industry Spotlight

BI extends development of Pharmaxis compound

16 May 2017 via Biotech Dispatch: A major boost for Pharmaxis (ASX:PXS) with Boehringer Ingelheim extending its development of the Sydney-based company’s PXS‐4728A.

Boehringer Ingelheim acquired PXS‐4728A from Pharmaxis in May 2015 with initial clinical development focused on finding a treatment for NASH (Non‐alcoholic Steatohepatitis), a debilitating liver disease.

Read more in Biotech Dispatch.